AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
February 16, 2017
-
February 02, 2017- If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major genotypes
-
January 27, 2017- Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent
-
January 25, 2017- Initiation of Phase 2 clinical trial programs in early Alzheimer's disease and progressive supranuclear palsy (PSP) is part of ongoing commitment to investigate ABBV-8E12 and tau-focused approaches to delay disease progression
-
January 24, 2017- If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis
-
January 19, 2017- This marks the seventh FDA approval and fifth disease indication for IMBRUVICA since the medication's initial approval in 2013
-
January 10, 2017
-
January 09, 2017- Collaborations will focus on key therapeutic areas, including oncology and immunology
-
January 09, 2017- 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR[12] with 8 weeks of G/P
-
December 22, 2016
-
December 19, 2016- If approved, G/P will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes
-
December 06, 2016- New Phase 2 data presented at the American Society of Hematology Annual Meeting highlight potential role of ibrutinib therapy beyond hematologic cancers
-
December 05, 2016- Data presented at the American Society of Hematology Annual Meeting show 48% overall response rate
-
December 05, 2016
-
December 04, 2016- New data available for ibrutinib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and in first-line follicular lymphoma (FL)
-
December 03, 2016- Nearly nine out of 10 patients (89%) with CLL/SLL achieve complete or partial response at five-year analysis
-
November 15, 2016- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis
-
November 14, 2016- If approved by the European Commission, HUMIRA will be the first and only treatment option for patients aged 12 and older with hidradenitis suppurativa (HS), a painful, chronic inflammatory skin disease.
-
November 11, 2016- 97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 weeks of G/P
-
November 04, 2016- Veliparib in combination with chemotherapy or radiation is being investigated in ongoing studies for advanced squamous non-small cell lung cancer (NSCLC)[1]
-
November 03, 2016- Results to be presented from ibrutinib clinical studies across multiple blood cancers
-
November 02, 2016
-
November 01, 2016
-
October 28, 2016
-
October 28, 2016- Reports Third-Quarter Diluted EPS of $0.97 on a GAAP Basis; Adjusted Diluted EPS of $1.21, Reflecting Growth of 7.1 Percent Over Third-Quarter 2015
-
October 19, 2016- Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis
-
October 10, 2016
-
October 06, 2016- New detailed results to be presented on primary and secondary efficacy and safety from two pivotal Phase 3 studies evaluating the use of Elagolix in endometriosis-associated pain
-
September 30, 2016- Breakthrough Therapy Designation granted based on Phase 2 clinical data for genotype 1 (GT1) patients who failed previous therapy with direct-acting antivirals (DAAs)
-
September 28, 2016- New site to expand the company's global operations for small molecule and biologics manufacturing
-
September 26, 2016- New Phase 2 open-label extension data to be presented on investigational biologic compound risankizumab, an anti-IL-23 monoclonal antibody, currently under investigation for moderate to severe chronic plaque psoriasis
-
September 26, 2016- If approved by the U.S. FDA, ibrutinib will be the first therapy specifically approved for patients with marginal zone lymphoma (MZL), a slow-growing form of non-Hodgkin's lymphoma, and the fifth new treatment indication for the medication
-
September 23, 2016- 98 percent of previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVR12 in Phase 3b GARNET study1
-
September 09, 2016
-
July 29, 2016- Reports Second-Quarter Diluted EPS of $0.98 on GAAP Basis; Adjusted Diluted EPS of $1.26, Reflecting Growth of 16.7 Percent Over Second-Quarter 2015
-
July 28, 2016- Trial will study efficacy and safety of venetoclax in combination with bortezomib and dexamethasone in patients who are considered sensitive or naïve to proteasome inhibitors who have received 1 to 3 prior lines of therapy for multiple myeloma(1)
-
July 25, 2016- New extended-release formulation is the first all-oral, co-formulated treatment containing the three direct-acting antiviral components of VIEKIRA PAK® for adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection
-
July 25, 2016- Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC
-
July 25, 2016- The CHMP opinion represents a positive advance toward approval of the 12-week regimen of VIEKIRAX with ribavirin for genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with or without compensated cirrhosis
-
July 11, 2016- DIPG are highly aggressive and difficult to treat brain tumors found at the base of the brain
-
July 07, 2016- Data from Phase 3 randomized, placebo controlled trial demonstrates that 46.6 percent of adult patients with moderate to severe psoriasis treated with HUMIRA® achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis
-
July 01, 2016
-
June 30, 2016- Non-infectious uveitis is an immune-mediated disease that can flare and impair vision
-
June 29, 2016- FDA also granted ibrutinib Orphan Drug Designation for this condition. There are currently no therapies specifically approved for cGVHD, a severe and potentially life-threatening condition in which transplanted cells from donor attack the patient's body
-
June 16, 2016
-
June 06, 2016- Findings from RESONATE™ (PCYC-1112), RESONATE™-2 (PCYC-1115), and HELIOS (CLL3001) studies. This press release corresponds to abstracts #7525 and #7520.
-
June 05, 2016- Results of expansion cohort of open-label Phase 1 study found no dose-limiting toxicities and frequent, reversible eye toxicities
-
June 05, 2016- Secondary objective demonstrated one-year overall survival rate in 32 percent of patients identified with high expression of delta-like protein 3 (DLL3) SCLC
-
June 03, 2016- AbbVie is dedicated to delivering innovative new therapies that significantly advance the standard of care
-
June 02, 2016- Twenty-six presentations evaluate either HUMIRA, investigational treatments or related topics in multiple autoimmune diseases
-
May 31, 2016- This decision follows April 29 recommendation from the Committee for Medicinal Products for Human Use (CHMP) in the EU in favor of approval
-
May 27, 2016Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple SclerosisApproval Supported by Largest and Longest Head-to-Head Phase 3 Study Conducted in Multiple Sclerosis (MS)
-
May 27, 2016- If approved by the European Commission, HUMIRA would be the first biologic treatment option in the European Union for certain patients with non-infectious intermediate, posterior and panuveitis
-
May 24, 2016- After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn's disease, the majority of whom had previously failed treatment with one or more TNF antagonists, achieved clinical remission with risankizumab compared with placebo(1)
-
May 19, 2016- Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in adult and pediatric patients
-
May 18, 2016- New data to be presented from clinical trials evaluating Venclexta™ (venetoclax) and IMBRUVICA® (ibrutinib)
-
May 09, 2016- Update to the IMBRUVICA U.S. Prescribing Information includes overall survival data from RESONATETM-2 study show significant improvements in previously untreated CLL/SLL patients with IMBRUVICA compared to chemotherapy (chlorambucil)
-
April 29, 2016- Recommendation follows recent approval by the U.S. FDA for this indication
-
April 28, 2016- Reports First-Quarter Adjusted Diluted EPS of $1.15, Up 22.3 Percent; GAAP Diluted EPS of $0.83
-
April 28, 2016- Rovalpituzumab tesirine (Rova-T) is a biomarker-specific antibody drug conjugate targeting cancer stem cell protein DLL3
-
April 25, 2016- Approval supported by TURQUOISE-III study showing 100 percent SVR12 (N=60/60) in chronic hepatitis C virus (HCV) infected genotype 1b patients with compensated cirrhosis (Child-Pugh A)
-
April 21, 2016- Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71
-
April 16, 2016- 97-98 percent SVR12 achieved with eight weeks of ABT-493 and ABT-530 in genotypes 1-3 hepatitis C virus patients without cirrhosis in SURVEYOR-1 and 2 studies(1,2)
-
April 15, 2016- VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study(1)
-
April 15, 2016- 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy with DAAs in a modified intent-to-treat analysis
-
April 14, 2016- 100 percent of genotype 1b patients, who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVR48 in a post-hoc analysis no matter whether baseline NS5A RAVs were present(1)
-
April 11, 2016- Novel BCL-2 inhibitor, approved as a single agent, provided 80 percent overall response rate in Phase 2 clinical study in patients with 17p deletion(1)
-
April 07, 2016
-
April 04, 2016- Pediatric Crohn's disease is a chronic, inflammatory condition of the gastrointestinal tract that can have a substantial physical and psycho-social impact.
-
March 30, 2016- Real-world and Phase 3/3b clinical trial data to be presented on VIEKIRAX® and EXVIERA® in genotype 1 and genotype 4 chronic hepatitis C virus infected patients
-
March 08, 2016
-
March 07, 2016- Anti-IL-23 antibody now in Phase 3 for psoriasis demonstrated greater efficacy over ustekinumab in Phase 2 clinical studies with a potential for quarterly dosing
-
March 04, 2016- Approval based on data from the Phase 3 RESONATE™-2 trial showing an 84% reduction in the risk of progression or death with IMBRUVICA compared to chlorambucil
-
March 02, 2016- New research includes further evaluation of the safety and efficacy of HUMIRA in patients with moderate to severe chronic plaque psoriasis, psoriatic arthritis and moderate to severe hidradenitis suppurativa (HS)
-
February 26, 2016- EU label expansion supported by high cure rates shown in TURQUOISE-III study, a dedicated Phase 3b study of VIEKIRAX + EXVIERA without ribavirin for 12 weeks
-
February 26, 2016- FDA also recently granted venetoclax Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) for the treatment of patients with AML
-
February 18, 2016
-
February 10, 2016- Study meets co-primary efficacy endpoints and full results will be presented at a medical conference in 2016
-
January 29, 2016- Reports Full-Year Adjusted EPS of $4.29, Up 29.2 Percent; GAAP EPS of $3.13
-
January 28, 2016- The Elagolix Phase 3 uterine fibroid clinical development program includes two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study.
-
January 28, 2016- An application is currently under review for single agent venetoclax treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including patients with the 17p deletion genetic mutation
-
January 21, 2016
-
January 20, 2016- Marks the second Breakthrough Therapy Designation for venetoclax
-
January 12, 2016· Priority Review granted by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) in adults who have received at least one prior therapy, including patients with 17p deletion
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
